About AVT
Browse Articles
Customer Services

Original article

Antiviral activity of 4-oxoquinoline-3-carboxamide derivatives against bovine herpesvirus type 5

Ana Maria V Pinto, José Paulo G Leite, Robson SS Marinho, Luana da SM Forezi, Pedro N Batalha, Fernanda da CS Boechat, Anna C Cunha, David O Silva, Ivson L Gama, Letícia V Faro, Maria CBV de Souza, Izabel Christina P Paixão

Corresponding author name: Izabel Christina P Paixão
Corresponding author e-mail: izabeluff@gmail.com

Citation: Antiviral Therapy 2020; 25:13-20
doi: 10.3851/IMP3329

Date accepted: 08 July 2019
Date published online: 20 September 2019


Background: Bovine herpesvirus type 5 is an important agent of meningoencephalitis in cattle and has been identified in outbreaks of bovine neurological disease in several Brazilian states. In recent years, oxoquinoline derivatives have become an important focus in antiviral drug research.

Methods: The cytotoxicity and anti BoHV-5RJ42/01 activity of a set of synthetic 4-oxoquinoline derivatives 4a-k were assayed on Madin–Darby Bovine Kidney cell and antiviral activity by plaque reduction assay.

Results: The most promising substance (4h) exhibited CC50 and EC50 values of 1,239 µM ±5.5 and 6.0 µM ±1.5, respectively, with an SI =206. Two other compounds 4j (CC50 = 35 µM ±2 and EC50 = 24 µM ±7.0) and 4k (CC50= 55 µM ±2 and EC50 = 24 µM ±5.1) presented similar inhibitory profile and selectivity indexes of 1.4 and 2.9, respectively. The results of the time-of-addition studies revealed expressive reduction of virus production (≥80%) in different stages of virus replication cycle except for compound 4h that slightly inhibited virus yield in the first 2 h post infection, but it showed expressive virus inhibition after this time.

Conclusions: All three compounds slightly interact with the virus on the virucidal assay and they are not able to block virus attachment and penetration. Antiviral effect of oxoquinoline 4h was more prominent than acyclovir which leads us to suggest compound 4h as a promising molecule for further anti-BoHV-5 drug design.


Copyright © 2020 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.